These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9665183)

  • 41. Multiple myeloma: new aspects of biology and treatment.
    Ozaki S; Kosaka M
    J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
    Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
    J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular mechanisms in multiple myeloma drug resistance.
    Nikesitch N; Ling SC
    J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents co-operatively induce apoptotic cell death in both sarcoma and myeloma cells.
    Suzuki H; Hotta T; Koyama T; Komagata M; Imakiire A; Yanase N; Yoshimoto T; Mizuguchi J
    Anticancer Res; 2003; 23(4):3247-53. PubMed ID: 12926060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway.
    van de Donk NW; Bloem AC; van der Spek E; Lokhorst HM
    Curr Pharm Des; 2006; 12(3):327-40. PubMed ID: 16454747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrin-mediated drug resistance in multiple myeloma.
    Damiano JS; Dalton WS
    Leuk Lymphoma; 2000 Jun; 38(1-2):71-81. PubMed ID: 10811449
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
    Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
    Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
    Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
    Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
    Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
    Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of Capon in multiple myeloma.
    Shen Y; Liu H; Gu S; Wei Z; Liu H
    Tumour Biol; 2017 Jul; 39(7):1010428317713674. PubMed ID: 28671047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloma Propagating Cells, Drug Resistance and Relapse.
    Karadimitris A; Chaidos A; Caputo V; Goudevenou K; Ponnusamy K; Xiao X
    Stem Cells; 2015 Nov; 33(11):3205-11. PubMed ID: 26302895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms of Resistance in Multiple Myeloma.
    Papadas A; Asimakopoulos F
    Handb Exp Pharmacol; 2018; 249():251-288. PubMed ID: 28315070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The plasma cell myeloma--molecular pathogenesis and target therapies].
    Hess U
    Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current drug therapy for multiple myeloma.
    Huang YW; Hamilton A; Arnuk OJ; Chaftari P; Chemaly R
    Drugs; 1999 Apr; 57(4):485-506. PubMed ID: 10235689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
    Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
    Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
    Catley L; Tai YT; Chauhan D; Anderson KC
    Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?
    Gieseler F; Rudolph P; Kloeppel G; Foelsch UR
    Int J Colorectal Dis; 2003 Nov; 18(6):470-80. PubMed ID: 12774240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.